The kit uses a simple drop of capillary blood and delivers the results in 48 hours electronically. Credit: Michal Jarmoluk / Pixabay.

Ethos Laboratories has launched the new fingerstick self-blood collection kit, Tru-Immune, for its Covid-19 neutralising antibody test.

The kit provides quantitative data regarding the viral blocking efficacy of neutralising antibodies.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Individuals can use the kit to measure their current immunity levels against Covid-19 safely, rapidly and efficiently in real-time with less pain.

Additionally, it will help people monitor their neutralising antibody level and reduce the chances to get infected.

The Tru-Immune uses a simple drop of capillary blood from the patients’ fingertip, which will be returned to Ethos through prepaid and priority postage. It delivers the results in 48 hours electronically.

Ethos Laboratories CEO Brian Kincaid said: “As we enter year three of the Covid-19 global pandemic, the question is no longer, ‘Do I have Covid-19 antibodies?’ Instead, people are asking themselves, ‘What level of protective immunity do I have against future infection and do I need a vaccine booster?’ These questions can now be answered with Tru-Immune.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Covid-19 neutralising antibody tests will provide information regarding the immunity levels against the disease in the individual.

This will help the healthcare provider to make decisions regarding vaccination and booster schedules.

Ethos noted that the neutralising antibody assays like Tru-Immune are expected to become the assay of choice to record natural immunity in states, where employers need proof to get exemption from mandates with regard to vaccines.

In April, Ethos introduced a new molecular test to detect key virus strains of SARS-CoV-2, including the UK (B.1.1.7), South Africa (B.1.351) and Brazil (P.1) variants.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now